Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 Aprile 2024 - 10:05PM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
on April 10, 2024, the Compensation Committee of Acadia’s Board of
Directors (the “Committee”) granted inducement awards consisting of
non-qualified stock options to purchase 21,659 shares of common
stock and 12,739 restricted stock units (“RSUs”) to six new
employees under Acadia’s 2023 Inducement Plan. The Compensation
Committee approved the awards as an inducement material to the new
employees’ employment in accordance with Nasdaq Listing Rule
5635(c)(4).
Each stock option has an exercise price per share equal to
$17.73 per share, Acadia’s closing trading price on April 10, 2024,
and will vest over four years, with 25% of the underlying shares
vesting on the one-year anniversary of the grant date and the
balance of the underlying shares vesting monthly thereafter over 36
months, subject to the new employees’ continued service
relationship with Acadia through the applicable vesting dates. The
RSUs will vest over four years, with 50% of the underlying shares
vesting on the second anniversary of the grant date, and the
balance of the underlying shares vesting in two equal annual
installments measured from the second anniversary of the grant
date, subject to the new employees’ continued service relationship
with Acadia through the applicable vesting dates. The awards are
subject to the terms and conditions of Acadia’s 2023 Inducement
Plan and the terms and conditions of an applicable award agreement
covering the grant.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only FDA-approved
drug to treat hallucinations and delusions associated with
Parkinson’s disease psychosis and the first and only FDA-approved
drug for the treatment of Rett syndrome. Our clinical-stage
development efforts are focused on Prader-Willi syndrome,
Alzheimer’s disease psychosis and multiple other programs targeting
neuropsychiatric symptoms in central nervous system disorders. For
more information, visit us at Acadia.com and follow us on LinkedIn
and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240419678876/en/
Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858)
261-2872 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950
ir@acadia-pharm.com
Grafico Azioni Acadia Pharmaceuticals (NASDAQ:ACAD)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Acadia Pharmaceuticals (NASDAQ:ACAD)
Storico
Da Set 2023 a Set 2024